Published in PLoS One on May 12, 2016
TWEAK/Fn14 Activation Participates in Skin Inflammation. Mediators Inflamm (2017) 0.75
Tumor necrosis factor superfamily ligand mRNA expression profiles differ between humans and mice during homeostasis and between various murine kidney injuries. J Biomed Sci (2017) 0.75
The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov (2008) 3.25
Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol (2012) 2.75
Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol (2012) 2.58
Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology (2010) 2.23
A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity (2001) 2.16
The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev (1996) 1.98
TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev (2003) 1.96
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol (1995) 1.74
Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin Immunol (2012) 1.74
The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol (2000) 1.73
TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev (2011) 1.70
Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med (2004) 1.67
Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J Clin Invest (1990) 1.67
Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol (2006) 1.63
The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis (2009) 1.59
The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem (1999) 1.53
TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol (1999) 1.52
The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J (2003) 1.52
A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol (2007) 1.52
Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol (2003) 1.50
The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol (2003) 1.47
The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol (2008) 1.43
TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol (2007) 1.42
Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med (2000) 1.40
Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine (1990) 1.35
Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int (2006) 1.34
TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J (2004) 1.33
Multiple pathways of TWEAK-induced cell death. J Immunol (2002) 1.32
The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol (2002) 1.29
Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS binding protein, and bactericidal/permeability-increasing protein. J Immunol (1994) 1.24
Slow release of soluble TNF receptors by monocytes in vitro. J Immunol (1994) 1.24
Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine (2009) 1.23
TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor-associated factors. Biochem Biophys Res Commun (2003) 1.21
The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci (2004) 1.18
Role of TWEAK in lupus nephritis: a bench-to-bedside review. J Autoimmun (2012) 1.15
Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem (2010) 1.13
Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int (2010) 1.11
Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol (2010) 1.09
Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med (2009) 1.07
TWEAK, a multifunctional cytokine in kidney injury. Kidney Int (2011) 1.06
Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J Biol Chem (2011) 0.99
TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J (2006) 0.99
The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukoc Biol (2012) 0.96
Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF-hybrid rats. Ren Fail (2000) 0.96
Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. J Immunol (1997) 0.95
No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies. J Leukoc Biol (2008) 0.95
Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. PLoS One (2012) 0.95
Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol (2012) 0.95
TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol Lett (2009) 0.94
Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. J Am Soc Nephrol (2014) 0.93
Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding. Immunobiology (2009) 0.93
TWEAK and the progression of renal disease: clinical translation. Nephrol Dial Transplant (2014) 0.91
Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. J Biol Chem (2013) 0.91
TWEAK and the central nervous system. Mol Neurobiol (2007) 0.90
TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. J Autoimmun (2015) 0.89
TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure. Front Immunol (2014) 0.89
TWEAK/Fn14 axis: the current paradigm of tissue injury-inducible function in the midst of complexities. Semin Immunol (2014) 0.88
TWEAK/Fn14 pathway promotes a T helper 2-type chronic colitis with fibrosis in mice. Mucosal Immunol (2013) 0.88
Fn14 in podocytes and proteinuric kidney disease. Biochim Biophys Acta (2013) 0.87
Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody. J Clin Immunol (1995) 0.85
Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med (2010) 0.85
TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease. Front Immunol (2013) 0.85
The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease. Cytokine Growth Factor Rev (2013) 0.85
Soluble tumor necrosis factor receptor 1 and 2 predict outcomes in advanced chronic kidney disease: a prospective cohort study. PLoS One (2015) 0.85
CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury. Nat Commun (2015) 0.83
Role of Fn14 in acute alcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol (2014) 0.82
The role of TWEAK/Fn14 in cardiac remodeling. Mol Biol Rep (2012) 0.82
TWEAK/Fn14 axis is a positive regulator of cardiac hypertrophy. Cytokine (2013) 0.81
Circulating TNF receptor 2 is associated with the development of chronic kidney disease in non-obese Japanese patients with type 2 diabetes. Diabetes Res Clin Pract (2013) 0.80
TWEAK-Fn14 as a mediator of acute kidney injury. Kidney Int (2011) 0.79